The firm also plans to make similar strategic moves in South Korea, Taiwan, Malaysia and Indonesia over the next three months.
Company CEO, president and founder, Rabinder Buttar explained how the UK-headquartered contract research organisation’s (CRO) global expansion strategy differs from its industry peers.
International standards
"Whilst other CROs have tended to acquire local companies in Asia Pacific to expand their geographical presence, Clintec has remained true to its strategy of organic growth and employing its own local staff. And therefore guaranteeing the same Clintec culture, values and international standards in the region from the start of its operations," said Dr Buttar.
"This has also allowed us to offer clients a high degree of flexibility in choosing the most suitable personnel for their projects, aligning our growth with those of our clients." The new regional offices build on the Clintec’s presence in the region, he added.
Global need
“Following a decade of building a strong regional hub in Bangalore, India, we are now tactically located in further Asian countries to meet big pharma’s global need for core resources including talent, experience and a wealth of localised clinical research knowledge,” said Dr Buttar.
The Bangalore hub was set up last August after Clintec secured financing from private equity group Elephant Capital in August last year. Elephant invested £8m ($12.5m) in Clintec for a 28.6 per cent stake.